Fmr LLC Has $18.37 Million Position in GH Research PLC (NASDAQ:GHRS)

Fmr LLC cut its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 7.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,745,445 shares of the company’s stock after selling 220,929 shares during the quarter. Fmr LLC owned about 0.05% of GH Research worth $18,367,000 as of its most recent SEC filing.

Separately, Lynx1 Capital Management LP increased its holdings in shares of GH Research by 19.8% during the 2nd quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company’s stock worth $46,252,000 after acquiring an additional 656,163 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on GHRS. Canaccord Genuity Group decreased their price objective on GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $39.00 price objective on shares of GH Research in a report on Wednesday, September 4th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of GH Research in a report on Wednesday, November 20th.

GH Research Stock Performance

NASDAQ:GHRS opened at $8.97 on Wednesday. The stock has a fifty day moving average price of $8.24 and a 200-day moving average price of $9.94. The company has a market cap of $466.69 million, a price-to-earnings ratio of -11.35 and a beta of 0.78. GH Research PLC has a fifty-two week low of $5.05 and a fifty-two week high of $14.99.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).